LithiumBank Resources

Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

08 June 2022

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced that five abstracts detailing clinical data for multiple non-alcoholic steatohepatitis (NASH) programs within the Company's portfolio were accepted for presentation at The International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom. The abstracts were published in the July supplement of the Journal of Hepatology.

Details of the Terns presentations at The International Liver Congress 2022 are as follows:

Oral Presentation
Title: Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study
Publication Number: OS123
Presenter: Cara Nelson
Date and Time: Saturday, June 25 6:15 p.m. BT

Poster Presentations
Title: Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in nonalcoholic steatohepatitis phase 2a LIFT study
Publication Number: SAT107
Presenter: Kris Kowdley

Title: Liver-distributed farnesoid X receptor agonist TERN-101 demonstrates potent target engagement with a favorable exposure-response profile in nonalcoholic steatohepatitis patients
Publication Number: SAT108
Presenter: Cara Nelson

Title: TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in nonalcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
Publication Number: SAT106
Presenter: Kris Kowdley

Title: Favorable safety profile of TERN-201, a highly selective inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study
Publication Number: SAT142
Presenter: Mazen Noureddin

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH, obesity and cancer. Terns’ pipeline includes four clinical stage development programs including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media
Jenna Urban
Berry & Company Public Relations
This email address is being protected from spambots. You need JavaScript enabled to view it. 


Sign Up To Get Daily Green Stock News In Your Inbox

Please review our Disclaimer and Privacy Policy before subscribing.

STOCK QUOTE

FEATURED GREEN STOCK

DevvStream

DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...

CLICK TO LEARN MORE

FEATURED GREEN STOCK

Else Nutrition

Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...

CLICK TO LEARN MORE

COPYRIGHT ©2022 GREEN STOCK NEWS